GlassScriptPhysician profile
Soha Mousa
NPI 1356300172
$10,405.43
in general payments reported to CMS, 2019-2025
23 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $1,849 · 2021: $1,658 · 2022: $1,528 · 2023: $1,635 · 2024: $1,391 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,546 · Consulting Fee: $985 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.70 |
| Consulting Fee | $985.00 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,466.25 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,945.32 | 2019-2025 | Prolia, Enbrel, Evenity |
| Abbvie INC. | $1,728.46 | 2019-2025 | |
| Ucb, INC. | $1,575.62 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $517.85 | 2019-2025 | Orencia |
| Lilly USA, LLC | $491.58 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $349.85 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $307.24 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $268.09 | 2019-2025 | |
| Radius Health, INC. | $140.39 | 2019-2023 | Tymlos |
| Genzyme Corporation | $136.32 | 2025 | |
| Pfizer INC. | $87.60 | 2019-2024 | |
| Horizon Therapeutics Plc | $69.85 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $52.90 | 2019 | |
| Aurinia Pharma U.S., INC. | $41.06 | 2022-2024 | Lupkynis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $40.52 | 2020 | |
| Ani Pharmaceuticals, INC. | $38.00 | 2022-2023 | Purified Cortrophin Gel |
| Organon LLC | $33.33 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $33.28 | 2020 | |
| Invivyd INC | $27.31 | 2025 | Pemgarda |
| Celgene Corporation | $24.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.30 | 2022 | |
| Novo Nordisk INC | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soha Mousa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.